Presentation on theme: "ABOUT ACUTE SEVERE HEPATITIS… Gerkens A, François E, Lucidi V, Moreno C, Donckier V, Bourgeois N, Mathieu A, Adler M Hôpital Erasme BASL – 11.12.2009."— Presentation transcript:
ABOUT ACUTE SEVERE HEPATITIS… Gerkens A, François E, Lucidi V, Moreno C, Donckier V, Bourgeois N, Mathieu A, Adler M Hôpital Erasme BASL – 11.12.2009
28-year old ♀ Past history: - Lifestyle: Caucasian, married, a 10-months-old son Policewoman, no recent travels No tobacco, alcohol, drugs, allergies Contraception: IUD Vaccination against HAV and HBV (Twinrix ® ) 2 nd injection late february 2009
Early march : Nausea, asthenia 15 d later: Jaundice with abnormal liver tests Hôpital Tivoli ↑ Bilirubin, ↓ PT Hôpital Erasme
Autoimmune hepatitis (AIH) Pathogenese: –Triggering factors: toxins, medications, infectious agents –Autoantigens –Genetic predisposition –Immunoregulatory networks Krawitt, EL. N Engl J Med 2006
Case report 1 ♂ 35 y AIH several days following serial immunizations (typhoïd, HAV, Diphteria/Tetanos, oral polio and mumps, measles and rubella) administrated on a single occasion Veerappan, GR. Digestive Diseases and Sciences 2005 Vaccination: another trigger ?
Vaccination: another trigger ? case report 2 ♀ 31 y AIH 11 days after hepatitis A virus and yellow fever vaccines Perumalswami, P. Seminars in liver disease 2009
Vaccines & autoimmune diseases (AID) Why vaccines are incriminated in AID ? –Theoretical background –Vaccines components –Incriminated vaccines
Theoretical background Infection Induce / trigger AID Genetically predisposed individuals Ag specific / non-specific way (molecular mimicry) Fail-safe mechanism (infection-induced autoimmunity) apply to host response to vaccination Wraith, D. The Lancet 2003
Incriminated vaccines Hepatitis B Vaccination –Multiple sclerosis: 2 cases reported Herroelen, L. The Lancet 1991 35 cases 1991-1997, 8w after vacc. Gout, O. Rev Neurol 1998 –Systemic erythematosus lupus: 10 cases related Agmon-Levin N, Lupus 2009 Haemophilus influenza type B (Hib) –Type 1 diabetes if given at ≥ 2 month Classen, JB. BMJ 1999
Vaccines & autoimmune diseases (AID) How to establish the causal relation ? –Case-controle studies WHO criteria: Consistency, Strenght, Specificity, Temporal relation –Biologic plausibility Identification of known biological markers of the identified AID in others vaccinee –Coincidence background cases Wraith, D. The Lancet 2003
Case-contole studies Association between type 1 diabetis and Hemophilus influenza type B vaccination: birth control study Karvonen, M. BMJ 1999 Vaccinations and the risk of relapse in multiple sclerosis Confavreux, C. N Engl J Med 2001 Hepatitis B vaccination and the risk of multiple sclerosis Ascherio, A. N Engl J Med 2001 Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case control study using the self-controlled case serie method Hocine, MN. Vaccine 2007 Risk of incident autoimmune diseases after vaccination : a large cohort study in the UK General Practice Research database Egbring, M. AASLD 2009
Coincidence background cases Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines Black, S. The Lancet, October 2009 Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events Callreus, T. Vaccine 2009
Conclusions Vaccination Cause of AIH ? Temporal relation: Yes Causal relation: No Impossible to be established on individual basis Clinical event has multiple or unknown causes
Case report Autoimmune hepatitis (AIH) –Definition –Epidemiology –Pathogenesis Vaccination: an other trigger for AIH ? –2 other case reports Vaccination and Autoimmune diseases (AID) –Why vaccines are incriminated in AID ? Theoretical background Vaccine components Incriminated vaccines –How to establish the causal relation ? Case-controle study Biologic plausibility Coincidence background cases Discussion Conclusion
CONCLUSIONS (2) Age-groups of autoimmune disorders = targets for vaccination programmes Increasing number of vaccination Better knowledge of mechanisms - by wich autoimmune responses are generated - how they might (not) lead to AID Real risk of vaccine-associated autoimmunity
Pathophysiology of AIH Liver injury in a patient with autoimmune hepatitis is the result of a cell-mediated immunologic attack. This attack is directed against genetically predisposed hepatocytes. Aberrant display of human leukocyte antigen (HLA) class II on the surface of hepatocytes facilitates the presentation of normal liver cell membrane constituents to antigen- processing cells. These activated cells, in turn, stimulate the clonal expansion of autoantigen-sensitized cytotoxic T lymphocytes. Cytotoxic T lymphocytes infiltrate liver tissue, release cytokines, and help to destroy liver cells. The reasons for the aberrant HLA display are unclear. It may be initiated or triggered by genetic factors, viral infections (eg, acute hepatitis A or B, Epstein-Barr virus infection),and chemical agents (eg, interferon, melatonin, alpha methyldopa, oxyphenisatin, nitrofurantoin, tienilic acid). The asialoglycoprotein receptor and the cytochrome mono-oxygenase P-450 IID6 are proposed as the triggering autoantigens. Some patients appear to be genetically susceptible to developing autoimmune hepatitis. This condition is associated with the complement allele C4AQO and with the HLA haplotypes B8, B14, DR3, DR4, and Dw3. C4A gene deletions are associated with the development of autoimmune hepatitis in younger patients. HLA DR3-positive patients are more likely than other patients to have aggressive disease, which is less responsive to medical therapy; these patients are younger than other patients at the time of their initial presentation. HLA DR4-positive patients are more likely to develop extrahepatic manifestations of their disease.
Association between type 1 diabetis and Hemophilus influenza type B vaccination: birth control study Karvonen, M. BMJ 1999 10-y follow-up study of more than 100 000 Finnish children involved in a clinical trial of the Hib vaccine: No increased risk of diabetes when children who had received 4 doses of vaccine at age 3, 4, 6 and 14-18 month were compared 1 dose at age 2 years
Vaccinations and the risk of relapse in multiple sclerosis Confavreux, C. N Engl J Med 2001 Case-crossover study Vaccinations: mono or multivalent / first adm. or booster 643 relapse: - 2.3% vaccinated during the 2-month risk period - 2.8 - 4.O% vaccinated during 1 or more of the 4 control periods RR: 0,71 (95% CI 0.4 -1.26) No increase in the specific short term risk of relapse associated with the HBVax
Hepatitis B vaccination and the risk of multiple sclerosis Ascherio, A. N Engl J Med 2001 121 700 nurses < 1976 116 671 nurses < 1989 192 MS with 645 controls RR MS associated with HBVax at any time before the onset of the disease: 0.7 (95% CI:0.5-1.6) RR MS associated with HBVax 2 y before the onset of the disease: 0.9 (95% CI:0.3-1.8) no assoc between HBVax and development of MS
Hepatitis B vaccination and first central nervous system demyelinating events: Reanalysis of a case control study using the self-controlled case serie method Hocine, MN. Vaccine 2007 Led to similar results: no strong association between HB vaccination and a first episod of CNS demyel. disease or MS and HBVax between 2 months or 1 year after vaccination Analyse based on all cases (matched and unmatched): -Relative incidence of first demyel. event =1.35 (95% CI 0.66-2.79) for 0-2 m post HBVax =1.78 (95% CI 0.97-3.27) for 2m-1y post HBVax Assoc between HBVax and first demyel. Event with indefinite post HBVax risk period 2.29 y after Appreciable reduction in possible biases/ gain in power
AASLD 2009 Autoimmune disease: RA, HLAB27 associated rheumatoïd disease, Rheumatoïd collagenosis, GN, Polyradiculoneuritis Exposed cohort: Unexposed cohort n38277 (6 to 60 y) 112185 AID23 55 RA 12 m 0.06% 0.05% RR associated HBVax: 1.23 (95% intervalle confidence) No significant association between HBVac and the studied AID
Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines Black, S. The Lancet, October 2009 Comparing observed rates with expected rates: 21.5 Guillain-Barré syndrome / 10 millions vaccinated 5.75 sudden death / " " " 86.3 optic neuritis / " " ♀ " pregnant ♀: 397 spont. abortion / 1 million " would be expected to occur within 6 weeks of vaccination as « COINCIDENCE BACKGROUND CASES » ! Age, sex, ethnic, geographical and seasonal characteristics (eg: priority groups in the H1N1 influenza vaccine) ! Methods used to develop these rates
Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. Callréus T, Svanström H, Nielsen NM, Poulsen S, Valentiner-Branth P, Hviid A Callréus TSvanström HNielsen NMPoulsen SValentiner-Branth P Hviid A Vaccine. 2009 May 14;27(22):2954-8. Epub 2009 Mar 13. Division of Vaccine, Statens Serum Institut, Copenhagen, Denmark. Determining incidence rates of potential adverse events before and after an immunisation programme is initiated, provides a useful framework for the evaluation of vaccine safety concerns. Human papillomavirus vaccination (HPV) of adolescent girls has recently been introduced in Denmark. Using a nationwide hospitalisation registry we estimated incidence rates of immune-mediated disorders before HPV vaccination in a cohort of 418,289 Danish girls aged 12- 15 years. We further estimated the expected number of cases of immune-mediated disorders occurring in temporal relationship to a hypothetical HPV vaccination schedule purely by chance. Our results and analytical approach provides a framework for the evaluation of adverse event reports following immunisation of adolescent girls.
New-generation vaccines 1° Autoimmune manifestations linked to infectious disease targeted by the vaccine (eg, group A streptococcal disease) 2° Potential molecular and immunologic mimicry between vaccine Ag and host components 3° Use of ad hoc experimental models of AID 4° Appropriate immunological investigations (eg, autoimmune serology) phase I-III clinical trials 5° Clinical surveillance of potential AI adverse effects and appropriate laboratory tests
Le squalène = produit intermédiaire du métabolisme du cholestérol, présent chez tous les organismes supérieurs (dont l’homme) dans divers sites, dont le sang ; il est un composant majeur de divers aliments, dont l’huile d’olive, avec une absorption de 60 à 80 % de la dose ingérée. La quantité injectée dans le vaccin est inférieure à égale à la quantité résorbée journalièrement par voie digestive. Aucune étude animale n’a montré de foeto ou embryotoxicité de ce produit naturel, qui disparaît en quelques jours du site de l’injection. Le squalène utilisé provient de foies de requins : sa contamination par de la vitamine A est au maximum de 0,33 mg/dose, largement inférieure à la dose quotidienne maximale pour la femme enceinte qui est de 3mg. Une analyse erronée des données avait attribué au squalène une responsabilité dans des problèmes de santé survenus après la guerre du Golfe, jusqu’au moment où on s’est rendu compte que les vaccins administrés aux soldats n’avaient jamais contenu de squalène… Les anticorps anti squalène, survenant naturellement chez de nombreuses personnes, et de manière croissante avec l’âge, n’ont pu être corrélés avec la survenue d’une pathologie ou l’emploi d’un vaccin contenant du squalène.
Le thiomersal est utilisé depuis les années ’30 dans la fabrication des vaccins, et plus particulièrement des flacons multidoses, afin de prévenir toute prolifération bactérienne ou fongique.Ce composé organique de mercure assure une meilleure protection que les autres conservateurs disponibles. Il s’agit d’éthyl-mercure, à métabolisation et élimination rapide (T ½ : moins d’une semaine), à ne pas confondre avec le méthyl-mercure, qui s’accumule lui longtemps dans l’organisme. Il est actuellement encore présent dans de nombreux vaccins multidoses à raison de 25 à 50 µg/dose, le Pandemrix en renfermant 5 µg/dose. L’emploi de vaccins contenant du thiomersal n’a jamais été lié épidémiologiquement avec une embryo ou foetotoxicité, ni avec des troubles neuropsychiatriques. Diverses instances, dont la FAO, considèrent que l’ingestion de 96-100 µg/semaine (dont 80% sont absorbés au niveau intestinal) ne présente pas de risque, y compris pour la femme enceinte. L’allergie de contact au thiomersal (présente chez 10-12% des gens) ne contre-indique en rien l’administration d’un vaccin le contenant
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Verstraeten T, Vaccine 2008 Verstraeten T Vaccine. 2008 Dec 2;26(51):6630-8. GlaxoSmithKline Biologicals, Rixensart, Belgium. firstname.lastname@example.org Newly licensed vaccines against human papillomavirus (HPV) and hepatitis B (HBV), and several vaccines in development, including a vaccine against genital herpes simplex virus (HSV), contain a novel Adjuvant System, AS04, composed of 3-O-desacyl-4' monophosphoryl lipid A and aluminium salts. Given the background incidence of autoimmune disorders in some of the groups targeted for immunisation with these vaccines, it is likely that autoimmune events will be reported in temporal association with vaccination, even in the absence of a causal relationship. The objective of this integrated analysis was to assess safety of AS04 adjuvanted vaccines with regard to adverse events (AEs) of potential autoimmune aetiology, particularly in adolescents and young adults. All randomised, controlled trials of HPV-16/18, HSV and HBV vaccines were analysed in an integrated analysis of individual data (N = 68,512). A separate analysis of the HPV-16/18 vaccine trials alone was also undertaken (N = 39,160). All data were collected prospectively during the vaccine development programmes (mean follow-up of 21.4 months), and included in the analysis up to a pre-defined data lock point. Reporting rates of overall autoimmune events were around 0.5% and did not differ between the AS04 and control groups. The relative risk (AS04/control) of experiencing any autoimmune event was 0.98 (95% confidence intervals 0.80, 1.21) in the integrated analysis and 0.92 (0.70, 1.22) in the HPV-16/18 vaccine analysis. Relative risks calculated overall, for disease category or for individual events were close to 1, and all confidence intervals around the relative risk included 1, indicating no statistically significant difference in event rates between the AS04 and control groups. This integrated analysis of over 68,000 participants who received AS04 adjuvanted vaccines or controls demonstrated a low rate of autoimmune disorders, without evidence of an increase in relative risk associated with AS04 adjuvanted vaccines
Your consent to our cookies if you continue to use this website.